Lincoln National Corp’s Novavax NVAX Stock Holding History

Lincoln National Corp’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-2,052	Closed	-$229K	–	819
2020 Q4	$229K	Buy	+2,052	New	+$218K	0.01%	661

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Lincoln National Corp's NVAX Position: Q1 2021 in Review

Lincoln National Corp sold out of Novavax (NVAX) in Q1 2021, closing a stake of 2,052 shares — an estimated $229K sold.

Lincoln National Corp first reported a position in NVAX in Q4 2020 and held it in 1 quarter. The position peaked at $229K in Q4 2020. 389 funds tracked by Wall St. Rank hold NVAX as of Q1 2021.

Lincoln National Corp reported no remaining Novavax position as of Q1 2021 after selling out during the quarter.
Lincoln National Corp sold 2,052 Novavax shares in Q1 2021, an estimated $229K.
Lincoln National Corp first reported a position in Novavax in Q4 2020 and held it in 1 quarter.
Lincoln National Corp's Novavax position peaked at $229K in Q4 2020.
389 funds tracked by Wall St. Rank held Novavax as of Q1 2021.

Based on Lincoln National Corp's 13F filing for Q1 2021, filed 10 May 2021.